NYSE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $17.87 +0.01 (+0.04%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$18.14 +0.27 (+1.49%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Takeda Pharmaceutical Stock (NYSE:TAK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Takeda Pharmaceutical alerts:Sign Up Key Stats Today's Range$17.78▼$17.8950-Day Range$16.58▼$19.0652-Week Range$12.99▼$19.10Volume2.05 million shsAverage Volume2.23 million shsMarket Capitalization$57.25 billionP/E Ratio52.55Dividend Yield2.69%Price TargetN/AConsensus RatingModerate Buy Company Overview Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder. The company also develops plasma-derived therapies and vaccines through its research and manufacturing operations. Founded in Osaka in 1781 by Chobei Takeda I, Takeda has evolved from a traditional Japanese medicine business into a multinational biopharmaceutical company. Its medicines and services are available in Japan, the United States, Europe and other markets worldwide. Takeda’s global expansion was significantly strengthened by its acquisition of Shire plc, completed in 2019. Christophe Weber has served as the company’s president and chief executive officer since 2014.AI Generated. May Contain Errors. Read More Takeda Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreTAK MarketRank™: Takeda Pharmaceutical scored higher than 30% of companies evaluated by MarketBeat, and ranked 738th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingTakeda Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTakeda Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Takeda Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-10.26% Earnings GrowthEarnings for Takeda Pharmaceutical are expected to decrease by -10.26% in the coming year, from $1.56 to $1.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Takeda Pharmaceutical is 52.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Takeda Pharmaceutical is 52.55, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.97.Price to Book Value per Share RatioTakeda Pharmaceutical has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Takeda Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.13% of the float of Takeda Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverTakeda Pharmaceutical has a short interest ratio ("days to cover") of 1.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Takeda Pharmaceutical has recently increased by 2.84%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldTakeda Pharmaceutical pays a meaningful dividend of 2.65%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthTakeda Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Takeda Pharmaceutical is 141.18%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 34.29% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.Read more about Takeda Pharmaceutical's dividend. News and Social Media2.1 / 5News Sentiment0.29 News SentimentTakeda Pharmaceutical has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Takeda Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,981,175.00 in company stock.Percentage Held by Insiders0.04% of the stock of Takeda Pharmaceutical is held by insiders.Percentage Held by Institutions9.17% of the stock of Takeda Pharmaceutical is held by institutions.Read more about Takeda Pharmaceutical's insider trading history. Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TAK Stock News HeadlinesReviewing Takeda Pharmaceutical (NYSE:TAK) and RYTHM (NASDAQ:RYM)October 2 at 5:46 AM | americanbankingnews.comAlpha Cognition (NASDAQ:ACOG) & Takeda Pharmaceutical (NYSE:TAK) Critical ContrastOctober 2 at 4:45 AM | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 3 at 1:00 AM | Stansberry Research (Ad)Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% RunOctober 1 at 6:29 PM | finance.yahoo.comCorus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in NepalOctober 1 at 1:28 PM | tmcnet.comWill Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline NarrativeOctober 1 at 1:28 PM | finance.yahoo.comTakeda Pharmaceutical (NYSE:TAK) Insider Lauren Rusckowski Duprey Sells 34,535 Shares of StockSeptember 16, 2026 | insidertrades.comAndrew Stewart Plump Sells 116,191 Shares of Takeda Pharmaceutical (NYSE:TAK) StockSeptember 5, 2026 | insidertrades.comSee More Headlines TAK Stock Analysis - Frequently Asked Questions How have TAK shares performed this year? Takeda Pharmaceutical's stock was trading at $15.59 at the beginning of the year. Since then, TAK shares have increased by 14.6% and is now trading at $17.8680. How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co. (NYSE:TAK) posted its quarterly earnings data on Thursday, July, 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.54. The firm had revenue of $7.50 billion for the quarter, compared to analysts' expectations of $7.13 billion. Takeda Pharmaceutical had a trailing twelve-month return on equity of 10.95% and a net margin of 3.80%. Read the conference call transcript. Does Takeda Pharmaceutical have any subsidiaries? Takeda Pharmaceutical subsidiaries include these companies: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and more. Who are Takeda Pharmaceutical's major shareholders? Takeda Pharmaceutical's top institutional shareholders include Versant Capital Management Inc. Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Julie So-Young Kim, Giles Richard Platford, Natalie Anne Marie Furney, Lauren Rusckowski Duprey, Agosti Marcello Pignagnoli, Gabriele Ricci, Andrew Stewart Plump, Awny Samaan Botros Farajallah, Ramy Riad Ahmed Ibrahim, Elaine Mary Shannon and Nicola Deidre Petal Greenway. View institutional ownership trends. How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE). Company Calendar Last Earnings7/30/2026Today10/03/2026Next Earnings (Estimated)10/29/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TAK's financial health is in the Green zone, according to TradeSmith. TAK has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TAK CIK1395064 Webwww.takeda.com Phone+81332782111Fax813-3278-2268Employees47,000Year Founded1781Profitability EPS (Trailing Twelve Months)$0.34 Trailing P/E Ratio52.55 Forward P/E Ratio11.45 P/E GrowthN/ANet Income-$1.01 billion Net Margins3.80% Pretax Margin-3.16% Return on Equity10.95% Return on Assets5.34% Debt Debt-to-Equity Ratio0.58 Current Ratio1.14 Quick Ratio0.62 Sales & Book Value Annual Sales$28.32 billion Price / Sales2.02 Cash Flow$3.11 per share Price / Cash Flow5.75 Book Value$15.41 per share Price / Book1.16Miscellaneous Outstanding Shares3,204,280,000Free Float3,203,001,000Market Cap$57.25 billion OptionableOptionable Beta-0.07 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:TAK) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
